Enanta Pharmaceuticals Inc - Asset Resilience Ratio

Latest as of March 2026: 40.94%

Enanta Pharmaceuticals Inc (ENTA) has an Asset Resilience Ratio of 40.94% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Enanta Pharmaceuticals Inc (ENTA) strategic investment index to assess the company's strategic physical and investment asset allocation.

Liquid Assets

$128.85 Million

Cash + Short-term Investments

Total Assets

$314.70 Million

All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2011–2025)

This chart shows how Enanta Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See ENTA equity to assets ratio to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Enanta Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ENTA stock market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$128.85 Million	40.94%
Total Liquid Assets	$128.85 Million	40.94%

Asset Resilience Insights

Very High Liquidity: Enanta Pharmaceuticals Inc maintains exceptional liquid asset reserves at 40.94% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Enanta Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio

Compare Enanta Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Cyclacel Pharmaceuticals Inc NASDAQ:CYCC	Biotechnology	-55.36%
Krystal Biotech Inc NASDAQ:KRYS	Biotechnology	23.06%
Verona Pharma PLC ADR NASDAQ:VRNA	Biotechnology	0.00%
Centessa Pharmaceuticals PLC ADR NASDAQ:CNTA	Biotechnology	33.37%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Hebei Changshan Biochem Pharma SHE:300255	Biotechnology	-0.03%
BB Biotech AG SW:BION	Biotechnology	0.05%

Annual Asset Resilience Ratio for Enanta Pharmaceuticals Inc (2011–2025)

The table below shows the annual Asset Resilience Ratio data for Enanta Pharmaceuticals Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-09-30	55.77%	$156.57 Million	$280.73 Million	-0.24pp
2024-09-30	56.01%	$210.95 Million	$376.65 Million	-5.54pp
2023-09-30	61.55%	$284.52 Million	$462.27 Million	+7.62pp
2022-09-30	53.93%	$205.24 Million	$380.59 Million	+11.56pp
2021-09-30	42.37%	$186.80 Million	$440.86 Million	-18.66pp
2020-09-30	61.03%	$299.52 Million	$490.79 Million	+3.05pp
2019-09-30	57.98%	$284.01 Million	$489.83 Million	-1.12pp
2018-09-30	59.10%	$244.83 Million	$414.23 Million	+10.73pp
2017-09-30	48.37%	$157.99 Million	$326.64 Million	-20.43pp
2016-09-30	68.80%	$193.51 Million	$281.28 Million	+18.60pp
2015-09-30	50.19%	$123.48 Million	$246.01 Million	+11.54pp
2014-09-30	38.65%	$60.06 Million	$155.41 Million	-40.53pp
2013-09-30	79.18%	$92.62 Million	$116.97 Million	+15.44pp
2012-09-30	63.75%	$33.25 Million	$52.16 Million	+0.55pp
2011-09-30	63.20%	$16.49 Million	$26.10 Million	--

pp = percentage points

About Enanta Pharmaceuticals Inc

NASDAQ:ENTA USA Biotechnology

Market Cap

$367.55 Million

Market Cap Rank

#14478 Global

#3391 in USA

Share Price

$12.64

Change (1 day)

+4.72%

52-Week Range

$6.49 - $16.85

All Time High

$126.37